[PDF][PDF] Down-titration of adalimumab and etanercept in psoriatic patients: a multicentre observational study
S Piaserico, P Gisondi, C De Simone… - Acta Dermato …, 2016 - iris.univr.it
RESULTS A total of 85 patients (55 (65%) males, 30 (35%) females; mean age 51±13.6
years) were included in the study. Patients' mean psoriasis duration was 21.7±10.8 years …
years) were included in the study. Patients' mean psoriasis duration was 21.7±10.8 years …
Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting
E Fonseca, R Iglesias, S Paradela… - Journal of …, 2015 - Taylor & Francis
Introduction: Knowledge on the efficacy and safety of adalimumab in psoriasis patients
switching from etanercept is scarce, especially on the influence that causes of etanercept …
switching from etanercept is scarce, especially on the influence that causes of etanercept …
Open‐label study of etanercept treatment in patients with moderate‐to‐severe plaque psoriasis who lost a satisfactory response to adalimumab
J Bagel, S Tyring, KC Rice, DH Collier… - British Journal of …, 2017 - academic.oup.com
Background Some patients with plaque psoriasis experience secondary failure of tumour
necrosis factor inhibitor therapy. Objectives To evaluate efficacy, safety and patient‐reported …
necrosis factor inhibitor therapy. Objectives To evaluate efficacy, safety and patient‐reported …
Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept
PPM Van Lümig, LLA Lecluse… - British Journal of …, 2010 - academic.oup.com
Background Knowledge on the sequential treatment of psoriasis with biologics with regard
to efficacy and safety is sparse. This also applies to the efficacy and safety of adalimumab in …
to efficacy and safety is sparse. This also applies to the efficacy and safety of adalimumab in …
Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: a case series
T Bhutani, J Koo - Journal of Dermatological Treatment, 2011 - Taylor & Francis
Background: Etanercept and adalimumab are the most widely used biologic agents for
psoriasis today. Large phase III trials have elucidated the much higher efficacy of …
psoriasis today. Large phase III trials have elucidated the much higher efficacy of …
Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept
R Bissonnette, C Bolduc, Y Poulin, L Guenther… - Journal of the American …, 2010 - Elsevier
BACKGROUND: The safety and efficacy of adalimumab in patients who have shown an
unsatisfactory response to etanercept are unknown. OBJECTIVE: We sought to evaluate the …
unsatisfactory response to etanercept are unknown. OBJECTIVE: We sought to evaluate the …
An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who …
R Vender - Journal of Drugs in Dermatology: JDD, 2011 - europepmc.org
Background The past several years have seen the approval of five different biologic agents
for the treatment of moderate to severe plaque psoriasis in the United States and Canada …
for the treatment of moderate to severe plaque psoriasis in the United States and Canada …
Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single‐centre, cohort study
Background A substantial proportion of patients with psoriasis do not respond, or lose initial
response to tumour necrosis factor‐α antagonists. One possible mechanism relates to …
response to tumour necrosis factor‐α antagonists. One possible mechanism relates to …
[HTML][HTML] Comparison of adalimumab and etanercept for the treatment of moderate to severe psoriasis: an indirect comparison using individual patient data from …
Objectives To compare outcomes between adalimumab and etanercept in the treatment of
moderate to severe plaque psoriasis. Methods Study groups included patients randomized …
moderate to severe plaque psoriasis. Methods Study groups included patients randomized …
Treating psoriasis with etanercept in Italian clinical practice: prescribing practices and duration of remission following discontinuation
A Arcese, N Aste, A Bettacchi, G Camplone… - Clinical drug …, 2010 - Springer
Background: Conventional antipsoriatic therapies are often administered until remission,
with treatment resumed in the case of relapse, in order to reduce the likelihood of …
with treatment resumed in the case of relapse, in order to reduce the likelihood of …